Ilhan Gokhan
Papers
1
Total Citations
10
H-Index
1
About
Ilhan Gokhan is a urologic researcher whose work centers on improving risk stratification in prostate cancer, particularly the critical gap between biopsy findings and final pathology. His most-cited study, "Over half of contemporary clinical Gleason 8 on prostate biopsy are downgraded at radical prostatectomy" (2017, 10 citations), directly challenges contemporary clinical guidelines that rely on the highest Gleason sum from biopsy cores to dictate treatment. By demonstrating that more than half of patients diagnosed with high-risk Gleason 8 disease on biopsy are actually downgraded to lower-risk pathology after radical prostatectomy, Gokhan’s work underscores a significant risk of overtreatment. This finding has important implications for clinical decision-making, urging caution before committing patients to aggressive therapies based solely on biopsy results. Gokhan’s research contributes to a more nuanced understanding of prostate cancer grading, helping to refine risk assessment and potentially spare men from unnecessary interventions. His work is a valuable resource for clinicians and researchers seeking to bridge the gap between biopsy-based risk classification and true pathological outcomes.
Research Focus
Key Achievements
Top Papers
- 1